Class information for:
Level 1: FOLLICULAR LYMPHOMA//RADIOIMMUNOTHERAPY//RITUXIMAB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
2691 2171 39.3 80%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
118 3       EPSTEIN BARR VIRUS//LYMPHOMA//HODGKINS DISEASE 69002
109 2             CHRONIC LYMPHOCYTIC LEUKEMIA//HODGKINS DISEASE//MANTLE CELL LYMPHOMA 25223
2691 1                   FOLLICULAR LYMPHOMA//RADIOIMMUNOTHERAPY//RITUXIMAB 2171

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 FOLLICULAR LYMPHOMA authKW 2332135 21% 37% 448
2 RADIOIMMUNOTHERAPY authKW 757707 12% 21% 260
3 RITUXIMAB authKW 481189 17% 9% 378
4 Y 90 IBRITUMOMAB TIUXETAN authKW 366526 2% 74% 35
5 IBRITUMOMAB TIUXETAN authKW 325122 2% 68% 34
6 ZEVALIN authKW 275624 1% 70% 28
7 YTTRIUM 90 IBRITUMOMAB TIUXETAN authKW 269645 1% 91% 21
8 I 131 TOSITUMOMAB authKW 239815 1% 95% 18
9 TOSITUMOMAB authKW 203065 1% 76% 19
10 INDOLENT LYMPHOMA authKW 195830 2% 41% 34

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Hematology 31678 37% 0% 801
2 Oncology 28022 58% 0% 1265
3 Radiology, Nuclear Medicine & Medical Imaging 1255 10% 0% 226
4 Transplantation 1066 5% 0% 108
5 Immunology 214 7% 0% 144
6 Medicine, Research & Experimental 152 4% 0% 94
7 Medicine, General & Internal 107 5% 0% 109
8 Pharmacology & Pharmacy 59 6% 0% 127
9 Cell & Tissue Engineering 27 0% 0% 9
10 Pathology 8 1% 0% 28

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 HLTH SCI NURSING BIOSTAT 58596 0% 83% 5
2 LYMPHOMA MYELOMA 39136 2% 6% 47
3 HEMATOL 30497 15% 1% 328
4 JAMES P WILMOT CANC 29281 2% 6% 34
5 AZIENDA OSPED S EUGENIO 28127 0% 100% 2
6 BRITISH LYMPHOMA INVEST OFF 28127 0% 100% 2
7 CATTEDRA SERV EMATOL 28127 0% 100% 2
8 HOSPICES CIVILS LYON HEAD 28127 0% 100% 2
9 TULANE CANC HEMATOL ONCOL FELLOWSHIP PROGRAM 28127 0% 100% 2
10 IST EMATOL ONCOL MED SERAGNOLI 27559 0% 20% 10

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LEUKEMIA & LYMPHOMA 39398 7% 2% 146
2 CLINICAL LYMPHOMA 33473 1% 13% 18
3 JOURNAL OF CLINICAL ONCOLOGY 26798 8% 1% 176
4 ANNALS OF ONCOLOGY 22127 5% 1% 114
5 CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 13864 2% 3% 38
6 SEMINARS IN ONCOLOGY 12408 3% 1% 68
7 CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 8902 1% 3% 22
8 HEMATOLOGICAL ONCOLOGY 8667 1% 3% 23
9 CLINICAL LYMPHOMA & MYELOMA 8507 1% 4% 14
10 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 8099 2% 1% 42

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 FOLLICULAR LYMPHOMA 2332135 21% 37% 448 Search FOLLICULAR+LYMPHOMA Search FOLLICULAR+LYMPHOMA
2 RADIOIMMUNOTHERAPY 757707 12% 21% 260 Search RADIOIMMUNOTHERAPY Search RADIOIMMUNOTHERAPY
3 RITUXIMAB 481189 17% 9% 378 Search RITUXIMAB Search RITUXIMAB
4 Y 90 IBRITUMOMAB TIUXETAN 366526 2% 74% 35 Search Y+90+IBRITUMOMAB+TIUXETAN Search Y+90+IBRITUMOMAB+TIUXETAN
5 IBRITUMOMAB TIUXETAN 325122 2% 68% 34 Search IBRITUMOMAB+TIUXETAN Search IBRITUMOMAB+TIUXETAN
6 ZEVALIN 275624 1% 70% 28 Search ZEVALIN Search ZEVALIN
7 YTTRIUM 90 IBRITUMOMAB TIUXETAN 269645 1% 91% 21 Search YTTRIUM+90+IBRITUMOMAB+TIUXETAN Search YTTRIUM+90+IBRITUMOMAB+TIUXETAN
8 I 131 TOSITUMOMAB 239815 1% 95% 18 Search I+131+TOSITUMOMAB Search I+131+TOSITUMOMAB
9 TOSITUMOMAB 203065 1% 76% 19 Search TOSITUMOMAB Search TOSITUMOMAB
10 INDOLENT LYMPHOMA 195830 2% 41% 34 Search INDOLENT+LYMPHOMA Search INDOLENT+LYMPHOMA

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 FREEDMAN, AS , (2014) FOLLICULAR LYMPHOMA: 2014 UPDATE ON DIAGNOSIS AND MANAGEMENT.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 89. ISSUE 4. P. 429-436 85 82% 23
2 FREEDMAN, A , (2015) FOLLICULAR LYMPHOMA: 2015 UPDATE ON DIAGNOSIS AND MANAGEMENT.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 90. ISSUE 12. P. 1172 -1178 88 81% 4
3 BAROSI, G , CARELLA, A , LAZZARINO, M , MARCHETTI, M , RAMBALDI, A , TARELLA, C , VITOLO, U , ZINZANI, PL , TURA, S , (2005) MANAGEMENT OF NODAL INDOLENT (NON MARGINAL-ZONE) NON-HODGKIN'S LYMPHOMAS: PRACTICE GUIDELINES FROM THE ITALIAN SOCIETY OF HEMATOLOGY, ITALIAN SOCIETY OF EXPERIMENTAL HEMATOLOGY AND ITALIAN GROUP FOR BONE MARROW TRANSPLANTATION.HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. VOL. 90. ISSUE 9. P. 1236-1257 139 66% 26
4 FREEDMAN, A , (2012) FOLLICULAR LYMPHOMA: 2012 UPDATE ON DIAGNOSIS AND MANAGEMENT.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 87. ISSUE 10. P. 988-995 80 84% 24
5 FREEDMAN, A , (2011) FOLLICULAR LYMPHOMA: 2011 UPDATE ON DIAGNOSIS AND MANAGEMENT.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 86. ISSUE 9. P. 769-775 79 86% 20
6 BENDANDI, M , (2008) AIMING AT A CURATIVE STRATEGY FOR FOLLICULAR LYMPHOMA.CA-A CANCER JOURNAL FOR CLINICIANS. VOL. 58. ISSUE 5. P. 305 -317 95 78% 20
7 HITZ, F , KETTERER, N , LOHRI, A , MEY, U , PEDERIVA, S , RENNER, C , TAVERNA, C , HARTMANN, A , YEOW, K , BODIS, S , ET AL (2011) DIAGNOSIS AND TREATMENT OF FOLLICULAR LYMPHOMA.SWISS MEDICAL WEEKLY. VOL. 141. ISSUE . P. - 80 88% 3
8 MCNAMARA, C , DAVIES, J , DYER, M , HOSKIN, P , ILLIDGE, T , LYTTELTON, M , MARCUS, R , MONTOTO, S , RAMSAY, A , WONG, WL , ET AL (2012) GUIDELINES ON THE INVESTIGATION AND MANAGEMENT OF FOLLICULAR LYMPHOMA.BRITISH JOURNAL OF HAEMATOLOGY. VOL. 156. ISSUE 4. P. 446 -467 85 71% 19
9 GANTI, AK , BOCIEK, RG , BIERMAN, PJ , ENKE, CA , VOSE, JM , ARMITAGE, JO , (2005) FOLLICULAR LYMPHOMA: EXPANDING THERAPEUTIC OPTIONS.ONCOLOGY-NEW YORK. VOL. 19. ISSUE 2. P. 213-228 92 81% 17
10 TAN, D , HORNING, SJ , (2008) FOLLICULAR LYMPHOMA: CLINICAL FEATURES AND TREATMENT.HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA. VOL. 22. ISSUE 5. P. 863 -+ 73 87% 20

Classes with closest relation at Level 1


Rank Class id link
1 10008 CD20//OFATUMUMAB//OBINUTUZUMAB
2 2606 NON HODGKINS LYMPHOMA//AGGRESSIVE LYMPHOMA//DIFFUSE LARGE B CELL LYMPHOMA
3 8759 FOLLICULAR LYMPHOMA//T1418//T1418 TRANSLOCATION
4 26758 BENDAMUSTINE//TREANDA//BENDAMUSTIN
5 5415 MANTLE CELL LYMPHOMA//T1114//SOX11
6 18119 PRETARGETING//PRETARGETED RADIOIMMUNOTHERAPY//MOL MED IMMUNOL
7 37341 IMPACT OF CANCER//IMPACT OF CANCER SCALE//EMPLOYMENT AFTER CANCER
8 7168 INTERIM PET//LYMPHOMA//INTERIM PET CT
9 13135 CLOFARABINE//CLADRIBINE//2 CHLORODEOXYADENOSINE
10 14101 IDIOTYPE//IDIOTYPE VACCINATION//IDIOTYPE VACCINE

Go to start page